Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
16 03 2022
Historique:
received: 06 10 2020
revised: 22 12 2020
accepted: 04 02 2021
pubmed: 13 2 2021
medline: 26 4 2022
entrez: 12 2 2021
Statut: ppublish

Résumé

The transcription factor Tbx5 controls cardiogenesis and drives Scn5a expression in mice. We have identified two variants in TBX5 encoding p. D111Y and p. F206L Tbx5, respectively, in two unrelated patients with structurally normal hearts diagnosed with long QT (LQTS) and Brugada (BrS) syndrome. Here, we characterized the consequences of each variant to unravel the underlying disease mechanisms. We combined clinical analysis with in vivo and in vitro electrophysiological and molecular techniques in human-induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs), HL-1 cells, and cardiomyocytes from mice trans-expressing human wild-type (WT) or mutant proteins. Tbx5 increased transcription of SCN5A encoding cardiac Nav1.5 channels, while repressing CAMK2D and SPTBN4 genes encoding Ca/calmodulin kinase IIδ (CaMKIIδ) and βIV-spectrin, respectively. These effects significantly increased Na current (INa) in hiPSC-CMs and in cardiomyocytes from mice trans-expressing Tbx5. Consequently, action potential (AP) amplitudes increased and QRS interval narrowed in the mouse electrocardiogram. p. F206L Tbx5 bound to the SCN5A promoter failed to transactivate it, thus precluding the pro-transcriptional effect of WT Tbx5. Therefore, p. F206L markedly decreased INa in hiPSC-CM, HL-1 cells and mouse cardiomyocytes. The INa decrease in p. F206L trans-expressing mice translated into QRS widening and increased flecainide sensitivity. p. D111Y Tbx5 increased SCN5A expression but failed to repress CAMK2D and SPTBN4. The increased CaMKIIδ and βIV-spectrin significantly augmented the late component of INa (INaL) which, in turn, significantly prolonged AP duration in both hiPSC-CMs and mouse cardiomyocytes. Ranolazine, a selective INaL inhibitor, eliminated the QT and QTc intervals prolongation seen in p. D111Y trans-expressing mice. In addition to peak INa, Tbx5 critically regulates INaL and the duration of repolarization in human cardiomyocytes. Our original results suggest that TBX5 variants associate with and modulate the intensity of the electrical phenotype in LQTS and BrS patients.

Identifiants

pubmed: 33576403
pii: 6130792
doi: 10.1093/cvr/cvab045
doi:

Substances chimiques

NAV1.5 Voltage-Gated Sodium Channel 0
Spectrin 12634-43-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1046-1060

Investigateurs

F Arribas (F)
J Pérez-Villacastín (J)
J J Alonso-Martín (JJ)
F Atienza (F)
J L López-Sendón (JL)
J Toquero (J)
A Hernández-Madrid (A)
E Delpón (E)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Paloma Nieto-Marín (P)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

David Tinaquero (D)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Raquel G Utrilla (RG)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Jorge Cebrián (J)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Andrés González-Guerra (A)

Fundación Centro Nacional de Investigaciones Cardiovasculares. CIBERCV, Madrid 28029, Spain.

Teresa Crespo-García (T)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Anabel Cámara-Checa (A)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Marcos Rubio-Alarcón (M)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

María Dago (M)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Silvia Alfayate (S)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

David Filgueiras-Rama (D)

Fundación Centro Nacional de Investigaciones Cardiovasculares. CIBERCV, Madrid 28029, Spain.

Rafael Peinado (R)

Department of Cardiology, Hospital Universitario La Paz. Instituto de Investigación Sanitaria la Paz. CIBERCV, Madrid 28046, Spain.

José Luis López-Sendón (JL)

Department of Cardiology, Hospital Universitario La Paz. Instituto de Investigación Sanitaria la Paz. CIBERCV, Madrid 28046, Spain.

José Jalife (J)

Fundación Centro Nacional de Investigaciones Cardiovasculares. CIBERCV, Madrid 28029, Spain.
Departments of Internal Medicine and Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA.

Juan Tamargo (J)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Juan Antonio Bernal (JA)

Fundación Centro Nacional de Investigaciones Cardiovasculares. CIBERCV, Madrid 28029, Spain.

Ricardo Caballero (R)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Eva Delpón (E)

Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid. Instituto de Investigación Gregorio Marañón. CIBERCV, Madrid 28040, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH